European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 24-29 , January 2009

Bosentan for patients with chronic thromboembolic pulmonary hypertension

  • Fabio Giuseppe Vassallo

      Affiliations

    • Department of Pneumology, University Hospital of Trieste, Trieste, Italy
    • ,
  • Metka Kodric

      Affiliations

    • Department of Pneumology, University Hospital of Trieste, Trieste, Italy
    • ,
  • Cleante Scarduelli

      Affiliations

    • Pneumology Unit, Hospital of Bozzolo-Mantova, Mantova, Italy
    • ,
  • Sergio Harari

      Affiliations

    • Department of Pneumology, Hospital S.Giuseppe, Milan, Italy
    • ,
  • Alfredo Potena

      Affiliations

    • Respiratory Unit, Arcispedale S.Anna, Ferrara, Italy
    • ,
  • Angelo Scarda

      Affiliations

    • Department of Pneumology, University Hospital of Trieste, Trieste, Italy
    • ,
  • Marco Piattella

      Affiliations

    • Respiratory Unit, Arcispedale S.Anna, Ferrara, Italy
    • ,
  • Roberto Cassandro

      Affiliations

    • Department of Pneumology, Hospital S.Giuseppe, Milan, Italy
    • ,
  • Marco Confalonieri

      Affiliations

    • Department of Pneumology, University Hospital of Trieste, Trieste, Italy
    • Corresponding Author InformationCorresponding author. Department of Pulmonology (SC Pneumologia), University Hospital of Trieste, Strada di Fiume 447, 34100 Trieste, Italy. Tel.: +39 0403994665; fax: +39 0403994668.

Received 18 August 2007 ,Revised 28 November 2007 ,Accepted 9 March 2008.

References 

  1. Fedullo PF, Auger WR, Kerr RM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345(20):1465–1472
  2. Pengo V, Lensing AWA, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257–2264
  3. Doyle RL, MacCrory D, Chennick RN, Simonneau G, Conte J. Surgical treatment/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:63s–71s
  4. Dartevelle P, Fadel E, Mussot S, Chapelier A, Hervé P, de Perrot M, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23(4):637–648
  5. Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly. 2007;137:573–580
  6. Kunieda T, Nakanishi N, Satoh T, Kyotani S, Okano Y, Nagaya N. Prognoses of primary pulmonary hypertension and chronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern Med. 1999;38:543–546
  7. Suntharalingam J, Machado RD, Sharples LD, Toshner MR, Sheares KK, Hughes RJ, et al. Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax. 2007;62:617–622
  8. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:S40–S47
  9. Bresser P, Pepke-Zaba J, Jaïs X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3(7):594–600
  10. American Thoracic Society and European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am J Respir Crit Care Med. 2000;161:646–664
  11. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117
  12. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144:1202–1218
  13. ATS statement single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med. 1995;152:2185–2198
  14. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schafers HJ, Welte T, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2363–2367
  15. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2599–2603
  16. Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006;28:138–143
  17. Seyfarth HJ, Hummerschmidt S, Pankau H, Winkler J, Wirtz H. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration. 2007;74(3):287–292
  18. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: experience and lessons learned in 1500 cases. Ann Thorac Surg. 2003;76:1457–1462
  19. Jamieson SW. Pulmonary thromboendarterectomy. Heart. 1998;79:118–120
  20. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thrombotic pulmonary hypertension. Circulation. 1990;81:1735–1743
  21. Riedel M, Stanek V, Widinsky J, Prerovsky I. Long term follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81:151–158
  22. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011–2020
  23. Kim NH, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, et al. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation. 2004;109:18–22
  24. Reesink HJ, Meijer RC, Lutter R, Boosma F, Jansen HM, Kloek JJ, et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circulation J. 2006;8:1058–1063
  25. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schäfers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002;105:1034–1036
  26. Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation. 2007;115:2153–2158
  27. Archibald CJ, Auger WR, Fedullo PF, Channick RN, Kerr KM, Jamieson SW, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med. 1999;160:523–528
  28. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417–1431
  29. Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation. 1997;95:1479–1486
  30. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–1502

PII: S0953-6205(08)00109-X

doi: 10.1016/j.ejim.2008.03.008

European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 24-29 , January 2009

Article Tools

* Image Usage & Resolution